Selling its cancer drugs to Servier leaves Agios more reliant on mitapivat.
The deal is a late entrant into 2020's top five mergers and acquisitions.
The company has spent five years buying in discontinued projects, and at last has managed to sell one of these on at a nice profit.
The much-heralded Gilead and Galapagos partnership takes a big knock as the US biotech cuts some of its losses with the doomed arthritis project.
An $880m buyout by Lilly shows that some gene therapy companies have not yet priced themselves out of the market.
The deal solves several problems for Astra, and ranks as biopharma’s fifth-biggest cross-border transaction.
Boehringer Ingelheim buys NBE-Therapeutics, the second Ror1-focused player to be taken out in just over a month.
Sage gets a big endorsement for zuranolone, but the markets say it should have waited until it had a stronger negotiating position.
As Regeneron’s antibody cocktail becomes the latest Covid-19 treatment to win US authorisation, Merck shows that the search for new options is not over.